AFP3d
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
has approved TEVIMBRA ® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell ...
Targeted Oncology3d
Tislelizumab Gains FDA Nod in Advanced Esophageal Cancer
Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...
KED Global5d
SillaJen: first to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determining the best dose for a cancer drug combination in clinical trials.The co ...
Indaptus Therapeutics initiates Phase 1 study of Decoy20
Indaptus Therapeutics (INDP) announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion ...
The Manila Times5d
RTI at Aerospace TechWeek 2025: Advancing Next-Generation Aviation and Defense Technology
Real-Time Innovations (RTI) is the infrastructure software company for smart-world systems. RTI Connext ® is the world's leading software framework for intelligent distributed systems. Uniquely, ...
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...
Targeted Oncology9d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Seeking Alpha16d
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash ...
MedPage Today17d
AI and Mammography; Breast Cancer and Sexual Well-Being; Malaria Drug for Cancer?
(Nature Communications) The FDA approved tislelizumab (Tevimbra) in combination with platinum-containing chemotherapy for the first-line treatment of unresectable or metastatic PD-L1-positive ...
PMLive18d
BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use
BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...
Cancer Therapy Advisor18d
Tevimbra Plus Chemotherapy Approved as First-Line Tx for Advanced Esophageal Cancer
The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.